(Q37439364)

20 August 2017

1 reference

title

Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications (English)

1 reference

20 August 2017

0 references

0 references

0 references

George L Bakris

1

1 reference

20 August 2017

Vivian A Fonseca

series ordinal

2

1 reference

20 August 2017

Kumar Sharma

series ordinal

3

1 reference

20 August 2017

Ernest M Wright

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

8 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

75

1 reference

20 August 2017

issue

12

1 reference

20 August 2017

page(s)

1272-1277

1 reference

The sodium/glucose cotransport family SLC5

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Active sugar transport in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Surprising versatility of Na+-glucose cotransporters: SLC5.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Molecular physiology of sodium-glucose cotransporters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Anatomical and developmental patterns of facilitative glucose transporter gene expression in the rat kidney

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Inhibitor binding in the human renal low- and high-affinity Na+/glucose cotransporters

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Na(+) -glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Management of type 2 diabetes: oral agents, insulin, and injectables

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Effects of intensive glucose lowering in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

https://api.crossref.org/works/10.1038%2FKI.2009.87

1 reference

7 January 2021

Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives substituted on the B ring

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing

1 reference

https://api.crossref.org/works/10.1038%2FKI.2009.87

7 January 2021

Identifiers

DOI

10.1038/KI.2009.87

1 reference

Dimensions Publication ID

20 August 2017

1051402716

0 references

1 reference